en
/
sv
About Elicera
Elicera in brief
Board
Team
Advisors
Elicera's history
Immuno-oncology
What is immuno-oncology?
CAR T-cell therapy
Oncolytic virus
Technology
CAR T-cell therapy
Challenges
Mode-of-action
Scientific publications
Pipeline
Pipeline
ELC-301
ELC-401
ELC-201
ELC-100
Clinical trials
Patent portfolio
Investors
Press Releases
Corporate Governance
the Share
Financial Reports
Financial Calendar
Events
Share issues
Analyst Coverage
News
News
Press Releases
Events
Contact
en
/
sv
News
2026
2025
2024
2023
2022
2021
2020
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Oct 12, 2022
2022
Press Release Non-regulatory
Elicera Therapeutics: PhD thesis describing the iTANK-platform awarded best of the year 2021 in Sweden in the field of gene and cell therapy
Non-regulatory Press Release
Read more
Sep 7, 2022
2022
News
LifeScientist interviews Di Yu
News
Read more
Aug 31, 2022
2022
News
Oncology in Sweden publishes an article by Magnus Essand on Elicera's iTANK platform and upcoming clinical study
News
Read more
Aug 22, 2022
2022
Press Release Regulatory
Elicera Therapeutics AB (publ) Interim Report 1 January – 30 June 2022
Regulatory Press Release
Read more
Aug 12, 2022
2022
Press Release Non-regulatory
Elicera Therapeutics announces participation in several industry and partnering conferences
Non-regulatory Press Release
Read more
Jun 2, 2022
2022
Press Release Regulatory
Elicera Therapeutics receives 2.5 million Euros in EU funding to fully finance a clinical phase I/II-trial with its CAR T-cell therapy, ELC-301
Regulatory Press Release
Read more
Apr 27, 2022
2022
Press Release Non-regulatory
Elicera Therapeutics successfully concludes preclinical proof-of-concept studies for oncolytic virus ELC-201 confirming the proposed mode-of-action
Non-regulatory Press Release
Read more
Apr 27, 2022
2022
News
Interviews with Magnus Essand and Gunilla Enblad at SWECARNET's education day April 27
News
Read more
Apr 26, 2022
2022
Press Release Regulatory
Elicera Therapeutics AB (publ) Interim Report 1 January – 31 March 2022
Regulatory Press Release
Read more
Apr 10, 2022
2022
News
Upsala Nya Tidning writes about Elicera's research and upcoming clinical studies
News
Read more
Apr 7, 2022
2022
News
Nordic Life Science News writes about the iTANK-publication
News
Read more
Apr 6, 2022
2022
News
Biostock makes a video interview with CSO, professor Magnus Essand, on the iTANK, publication.
News
Read more
Apr 4, 2022
2022
Press Release Regulatory
Elicera Therapeutics publishes scientific article in Nature Biomedical Engineering on the iTANK-platform and data indicating its universal compatibility with other CAR T-cell therapies
Regulatory Press Release
Read more
Mar 1, 2022
2022
News
Elicera featured in Life Science Sweden's perspective on CAR T-cell therapies
News
Read more
Feb 24, 2022
2022
Press Release Non-regulatory
Elicera Therapeutics’ Chief Scientific Officer, Professor Magnus Essand, to present at SWECARNET’s Educational Day 2022
Non-regulatory Press Release
Read more
Feb 4, 2022
2022
Press Release Regulatory
Elicera Therapeutics publishes annual report for 2021
Regulatory Press Release
Read more
Jan 25, 2022
2022
Press Release Regulatory
Elicera Therapeutics AB (publ) Interim Report 1 January – 31 December 2021
Regulatory Press Release
Read more
Jan 20, 2022
2022
News
Interview and summary of 2021 in Biostock
News
Read more
Jan 19, 2022
2022
News
Elicera in Nordic Life Science - Vinnova grant
News
Read more
Jan 18, 2022
2022
Press Release Non-regulatory
Elicera Therapeutics secures 5 million SEK in funding from Vinnova to develop an automated CAR T-cell manufacturing process
Non-regulatory Press Release
Read more
Previous
+ Load more
5 / 8
Sign up for Press Releases
By filling out the form you are approving that Elicera stores your information. Read more about our integrity policy
here
.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
By continuing to browse this website you agree to cookies being stored on your device in order to improve the experience and analyze how it is being used. Read more in our
Integrity policy
.
Deny
Accept